*Antonio Cássio Assis Pellizzon Department Of Radiation Oncology, Brazil
*Corresponding Author: Antonio Cássio Assis Pellizzon
Department Of Radiation Oncology, Brazil Email:firstname.lastname@example.org
Published on: 2018-10-25
Rosai–Dorfman disease (RDD) also known as histiocytosis with lymphadenopathy is uncommon, often self-limiting benign, not– Langerhans-cell histiocytic proliferative disorder. It usually affects young adults and children, with no predilection for sex. More than 80% of patients present with painless cervical lymphadenopathy, with or without fever. Other presentation sites include upper aero-digestive tract, orbits, and the paranasal sinuses. Extra nodal involvement can occur from 20% to more than 40% of cases, and common sites of involvement include the skin, upper airway, soft tissue, bones kidney, lower respiratory tract, liver, orbit and central nervous system. Treatment is not necessary for most instances, but some patients, when symptomatic, may require medical intervention. There is no established guideline for the management of this condition and various therapeutic modalities are used, including surgery, radiotherapy and or chemotherapy.
Proliferative Disorder; Radiotherapy; Surgery
Rosai–Dorfman disease (RDD) is an uncommon, often self-limiting benign, not–Langerhans-cell histiocytic proliferative disorder, first described by Rosai and Dorfman in 1969 as sinus histiocytosis with lymphadenopathy [1,2]. This rare benign histiocyte disorder can have nodal and extranodal manifestations, with no concordance in the literature in this form of presentation, being the last one described from up to 20% to more than 40% of patients, in special elderly. The diagnosis is based on the cytologic and clinical findings [1-4]. Treatment is not necessary for most instances , but some patients, when symptomatic, may require medical intervention. In the absence of established guidelines for the management of this condition, various therapeutic modalities are used, including surgery, radiotherapy and or chemotherapy for disease manifestations [3,6].